Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for Epstein-Barr virus-related tumor has been reported in the published literature.
No clinical trials have been registered for Epstein-Barr virus-related tumor.
89 publications have been identified in PubMed for Epstein-Barr virus-related tumor. Research spans Review / Meta-Analysis (28%), Basic Science / Preclinical (21%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 25 | 28% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Epstein-Barr virus-related tumor
Laboratory research
19 |
21% |
Patient case studies | 18 | 20% |
Disease patterns and progression | 13 | 15% |
Testing and diagnosis research | 8 | 9% |
Other research | 2 | 2% |
Clinical study results | 2 | 2% |
New treatment approaches | 2 | 2% |
Avsar H (2026). [PMID: 42049331](https://pubmed.ncbi.nlm.nih.gov/42049331/). *Anticancer Res*. [Case Report / Case Series]
Wu Y (2026). [PMID: 42071869](https://pubmed.ncbi.nlm.nih.gov/42071869/). *Medicine (Baltimore)*. [Case Report / Case Series]
Hirabayashi M (2026). [PMID: 41947331](https://pubmed.ncbi.nlm.nih.gov/41947331/). *Int J Cancer*. [Review / Meta-Analysis]
Wu F (2026). [PMID: 41724953](https://pubmed.ncbi.nlm.nih.gov/41724953/). *J Nanobiotechnology*. [Basic Science / Preclinical]
Yudie L (2026). [PMID: 41925921](https://pubmed.ncbi.nlm.nih.gov/41925921/). *Clin Exp Med*. [Review / Meta-Analysis]
Oussama K (2026). [PMID: 42115812](https://pubmed.ncbi.nlm.nih.gov/42115812/). *Allergol Immunopathol (Madr)*. [Case Report / Case Series]
Li SC (2026). [PMID: 41854586](https://pubmed.ncbi.nlm.nih.gov/41854586/). *JAMA Oncol*. [Diagnostic / Biomarker]
Zheng W (2026). [PMID: 41775689](https://pubmed.ncbi.nlm.nih.gov/41775689/). *Cell Death Dis*. [Basic Science / Preclinical]
Rao Z (2026). [PMID: 41942950](https://pubmed.ncbi.nlm.nih.gov/41942950/). *BMC Pediatr*. [Case Report / Case Series]
Fujimori D (2026). [PMID: 41635385](https://pubmed.ncbi.nlm.nih.gov/41635385/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning Epstein-Barr virus-related tumor
Updated Mar 1, 2026
A case report highlights the successful management of suspected Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with BRAF-mutant cholangiocarcinoma. The treatment involved immune checkpoint inhibitors and BRAF/MEK inhibitors, showcasing potential therapeutic strategies for this rare condition.
A case study highlights the diagnostic and therapeutic challenges of an Epstein-Barr virus (EBV)-associated smooth muscle tumor in a patient with HIV. This research underscores the complexities of managing rare tumors linked to viral infections in immunocompromised individuals.